Glioblastoma (GBM) is among the most formidable of all human cancers. Despite decades of effort, patient outcomes have changed little. The reasons are now all…
Read More
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Trogenix has developed a platform for generating ‘synthetic super-enhancers’ that…
Read More
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy TGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that…
Read More
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour…
Read More
January 12-15, 2026, San Francisco.
Read More
November 17-20, 2025, London, UK
Read More